期刊文献+

三维适形放射治疗同步泰素治疗晚期食管癌

Three Dimensional Conformal Radiotherapy Combined with Taxol for Advanced Esophageal Carcinoma
暂未订购
导出
摘要 [目的]探讨局部晚期及术后复发性食管癌三维适形放射治疗(3DCRT)同步泰素化疗的临床疗效。[方法]36例局部晚期和术后复发性食管癌采用3DCRT结合泰素化疗(综合组)17例,单独应用3DCRT(对照组)19例。[结果]综合组和对照组疼痛缓解率分别为88.2%和78.9%,有效(CR+PR)率分别为88.2%和84.2%,两组均无显著性差异(P>0.05)。综合组1年、2年生存率分别为87.5%、62.5%,高于对照组(79%、28.7%),但无显著性差异(P=0.056),2年局部控制率分别为35.29%和21.05%,无显著性差异(P=0.06)。远处转移率分别为35.2%和63.1%,有显著性差异(P=0.045)。毒副反应方面两组相似(P>0.05)。[结论]局部晚期和术后复发性食管癌临床上行三维适形放射治疗配合化疗可明显降低远处转移率及提高患者的近期生存率。 [Purpose] To explore the effect of locally advanced or recurrent esophageal carcinoma treated by three dimensional conformal radiotherapy (3D-CRT)combined with taxol chemotherapy (CT). [Methods] Thirty-six cases with locally advanced or recurrent esophageal carcinoma were divided into combined group (3D-CRT plus taxol, 17 cases) and control group (3D-CRT alone, 19 cases). [Results] The pain-alleviation rates in combined group and control group were 88.2% and 78.9%, the overall response(CR+PR) rates were 88.2% and 84.2% respectively, with no significant difference (P〉0.05). In combined group the 1-year and 2-year survival rates were 87.5% and 62.5%, which were higher than those in control group (79.0% and 28.7%), with no significant difference (P=0.056). The 2-year local control rates in the 2 groups were 35.29% and 21.05%, with no significant difference (P=-0.06). The distant metastasis rates were 35.2% and 63.1%, with significant difference (P=0.045). The toxicities were similar in the two groups (P〉0.05). [Conclusion] 3D-CRT combined with chemotherapy can significantly reduce the distant metastasis rate and improve short-term survival in locally advanced or recurrent esophageal carcinoma.
出处 《肿瘤学杂志》 CAS 2008年第4期299-301,共3页 Journal of Chinese Oncology
关键词 食管肿瘤 放射疗法 适形 药物疗法 esophageal neoplasms radiotherapy, conformal drug therapy
  • 相关文献

参考文献8

  • 1殷蔚伯.胸部肿瘤.见:殷蔚伯、谷铣之主编,肿瘤放射治疗学[M].北京:北京医科大学中国协和医科大学联合出版社,2002.8598-8621.
  • 2Smalley SR, Gunderson LL, Reddy EK, et al. Radiotherapy alone in esophageal carcinoma:current management and future directions of adjuvant, curative palliative approaches[J]. Seroin Oncol, 1994, 21(4):467-473.
  • 3王牧民,娄云峰,黄静.放射治疗联合化疗治疗食管癌的临床疗效观察[J].中国肿瘤临床与康复,2007,14(1):62-64. 被引量:2
  • 4Sai H, Mitsumori M, Yamauchi C, et al. Concurrent chemoradiotherapy for esophageal cancer: comparison between intermittent standard-dose cisplatin with 5-fluorouracil and daily low-dose cisplatin with continuous infu- sion of 5-fluorouracil[J]. Int J Clin Oncol, 2004, 9(3):149- 153.
  • 5Liebmann J, Cook JA, Fisher J, et al. Changes in radiation survival curve parameters in human tumor and rodent cells exposed to paclitaxel (Taxol)[J]. Int J Radiat Oncol Biol Phys, 1994, 29(3): 559-564.
  • 6Liebmann J, Cook JA, Fisher J, et al. In vitro studies of taxol as a radiation sensitizer in human tumor cells [J]. J Nantl Cancer Inst, 1999, 86(6):441-446.
  • 7Zanelli GD, Quaia M, Robieux I, et al. Paclitaxel as a radiosensitiser: a proposed schedule of administration based on in vitro data and pharmacokinetic calculation[J]. Eur J Cancer, 1997, 33(3):486-492.
  • 8Choy H, Devore RF, Hande KB. A phase Ⅱ study of paclitaxel, carboplatin and concurrent hyperfraction radiotherapy for locally advanced inoperable non-small cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2000, 47(4): 931-937.

二级参考文献6

共引文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部